Malic Acid

PreclinicalSmall molecule

TThe First Affiliated Hospital of Xinxiang Medical College

Malic Acid is one of 17 small molecule programs targeting Xerostomia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

XerostomiaActive, not recruiting

XerostomiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

38 competitors in Xerostomia

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Approved

3 2

Decadron

AAspen Global Incorporated

Approved

—3

Ethyol

LLegacy Health System

Approved

—4

Evoxac

CCosette Pharmaceuticals, Inc.

Approved

1 5

Biotene

UUniversity of Southern California

Approved

1 6

Aloevera

GGovernment Dental College and Research Institute, Bangalore

Phase 3

1 7

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 2

1 8

Amifostine Trihydrate

GGynecologic Oncology Group

Phase 2

1 9

Mesenchymal Stem Cell

RRohto Pharmaceutical Co., Ltd.

Phase 2

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Patients With Solid Tumors

NCT07325123

Clinical

Trials by Indication[1]

Xerostomia2 trials

Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity

Completed·UUniversidad de Granada·Phase 2/3·NCT01652001·185 enrolled

Malic Acid in Treatment of Xerostomia

Unknown status·HHams Hamed Abdelrahman·N/A·NCT04756986·52 enrolled

Patients With Solid Tumors1 trial

Malic Acid Supplementation Combined With Immunotherapy in Patients With Solid Tumors

Not yet recruiting·TThe First Affiliated Hospital of Xinxiang Medical College·Phase 1·NCT07325123·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Malic Acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Malic Acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Malic Acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Xinxiang Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Xinxiang Medical College

Malic Acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Xerostomia2 trials

Patients With Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News